Overview of 4Q sales trends for Pfizer medicines

AP News
|
Posted: Jan 31, 2012 5:39 PM
Overview of 4Q sales trends for Pfizer medicines

Here are sales figures for the fourth quarter for top-selling Pfizer prescription drugs:

PRODUCT NAME MAIN CONDITION/USE 4Q 2011 SALES 4Q 2010 SALES PERCENT CHANGE

Lipitor High cholesterol $2 billion $2.63 billion down 24 percent

Lyrica Fibromyalgia/pain $998 million $821 million up 22 percent

Enbrel (outside U.S.) Rheumatoid arthritis $925 million $865 million up 7 percent

Prevnar 7/Prevnar 13 Pneumococcal vaccine $916 million $1.05 billion down 15 percent

Celebrex Pain $667 million $622 million up 7 percent

Viagra Erectile dysfunction $523 million $499 million up 5 percent

Norvasc High blood pressure $364 million $386 million down 6 percent

Zyvox MRSA infections $318 million $300 million up 6 percent

Xalatan Glaucoma $290 million $462 million down 37 percent

Sutent Multiple cancers $317 million $295 million up 7 percent

___

Note: Sales changes include 1 percent benefit from favorable currency exchange rates.

Source: Pfizer Inc.